Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3527999 | 0.91 | CYP11B2 (0.45) | CYP11B1CYP11B2KDM4EALDH1A1ADORA2A | |
| SCHEMBL1463119 | 0.85 | CYP11B2 (0.49) | CYP11B1CYP11B2KDM4EALDH1A1ADORA2A | |
| SCHEMBL3528023 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1ADORA2AADORA1USP2 | |
| SCHEMBL2958151 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1ADORA2AADORA1USP2 | |
| SCHEMBL2648034 | 0.79 | GABRA1 (0.42) | CYP11B1CYP11B2KDM4EALDH1A1ADORA2A | |
| SCHEMBL26923403 | 0.79 | CYP11B2 (0.57) | CYP11B1CYP11B2KDM4EALDH1A1USP2 | |
| SCHEMBL28445916 | 0.79 | CYP11B1 (0.44) | CYP11B1CYP11B2KDM4EALDH1A1GCGR | |
| SCHEMBL2954914 | 0.78 | ALDH1A1 (0.56) | CYP11B1CYP11B2KDM4EALDH1A1ADORA1 | |
| SCHEMBL27514116 | 0.76 | KDM4E (0.49) | CYP11B1CYP11B2KDM4EALDH1A1ADORA2A | |
| SCHEMBL957251 | 0.75 | MAP4K4 (0.50) | ALDH1A1ADORA2AGCGRMAPK14LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-11591290-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591290-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3285757-B1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3285757-B1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20210161864-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210161864-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210024458-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | ONCTERNAL THERAPEUTICS, INC (US) | 2021-01-28 | — | — | US | disclosed |
| US-7405234-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| WO-2008017381-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | WO | disclosed |
| EP-1506178-A4 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1506178-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CYP11B1 10/4885CYP11B2 17/4885KDM4E 1161/4885 |
| US-20210161864-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE | AR, BRCA1, FSHR | CYP11B1 2989/4885CYP11B2 2917/4885KDM4E 1046/4885 |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | AR, BRCA1, FSHR | CYP11B1 2989/4885CYP11B2 2917/4885KDM4E 1046/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | CYP11B1 9/4885CYP11B2 14/4885KDM4E 1539/4885 |
| US-11591290-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, FSHR, UBE2V1 | CYP11B1 2964/4885CYP11B2 2677/4885KDM4E 212/4885 |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | AR, ESRRA, SHBG | CYP11B1 14/4885CYP11B2 15/4885KDM4E 1108/4885 |
| US-20210024458-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, FSHR, UBE2V1 | CYP11B1 2964/4885CYP11B2 2677/4885KDM4E 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.